print-icon
print-icon

Blood Thinners & Anti-Obesity Shots Dominate Medicare Drug Spending

Tyler Durden's Photo
by Tyler Durden
Authored...

From diabetes injectables to blockbuster blood thinners, a handful of drugs account for a sizable share of Medicare’s pharmacy bill.

This visualization, via Visual Capitalist's Pallavi Rao, ranks the most common drugs by total Medicare spending in 2023, sourced from Centers for Medicare & Medicaid Services

It tracks every claim, dosage, and dollar flowing through Medicare Part D, the federal prescription-drug benefit.

Blood Thinners Are America’s Most Common Drug

Eliquis (generic name: Apixaban) alone racked up $18.3 billion in Medicare spending in 2023, nearly double the next drug, Ozempic.

Alongside Xarelto, anticoagulants accounted for over $24 billion in 2023.

RankCountryRegionYears in Poor HealthHALE, 2021Average Life Expectancy, 2025
1🇧🇭 BahrainAsia17.464.281.6
2🇴🇲 OmanAsia17.363.280.5
3🇸🇿 EswatiniAfrica16.947.564.4
4🇶🇦 QatarAsia16.566.282.7
5🇧🇼 BotswanaAfrica16.353.169.4
6🇦🇫 AfghanistanAsia16.150.466.5
7🇦🇪 UAEAsia15.967.383.2
8🇺🇸 U.S.Northern America15.763.979.6
9🇵🇪 PeruSouthern America15.163.078.1
10🇱🇧 LebanonAsia14.963.278.1
11🇳🇦 NamibiaAfrica14.952.867.7
12🇲🇻 MaldivesAsia14.866.781.5
13🇧🇷 BrazilSouthern America14.461.876.2
14🇮🇳 IndiaAsia14.458.172.5
15🇲🇿 MozambiqueAfrica14.349.764.0
16🇮🇷 IranAsia14.164.078.1
17🇲🇰 North MacedoniaEurope14.063.777.7
18🇲🇽 MexicoAmericas14.061.475.4
19🇫🇲 MicronesiaOceania13.957.971.8
20🇨🇱 ChileSouthern America13.867.781.5
21🇨🇺 CubaAmericas13.864.678.4
22🇪🇷 EritreaAfrica13.855.469.2
23🇸🇰 SlovakiaEurope13.864.978.7
24🇿🇦 South AfricaAfrica13.752.866.5
25🇿🇲 ZambiaAfrica13.753.066.7
26🇬🇷 GreeceEurope13.668.682.2
27🇬🇹 GuatemalaAmericas13.659.372.9
28🇧🇬 BulgariaEurope13.662.476.0
29🇸🇷 SurinameSouthern America13.660.373.9
30🇦🇺 AustraliaOceania13.670.684.2
31🇬🇾 GuyanaSouthern America13.656.870.4
32🇱🇸 LesothoAfrica13.644.658.2
33🇨🇷 Costa RicaAmericas13.667.681.2
34🇸🇦 Saudi ArabiaAsia13.665.679.2
35🇫🇷 FranceEurope13.570.183.6
36🇺🇾 UruguaySouthern America13.565.078.5
37🇵🇱 PolandEurope13.565.579.0
38🇪🇨 EcuadorSouthern America13.564.377.8
39🇨🇿 CzechiaEurope13.466.780.1
40🇮🇹 ItalyEurope13.470.684.0
41🇸🇧 Solomon IslandsOceania13.457.470.8
42🇧🇸 BahamasAmericas13.461.574.9
43🇲🇦 MoroccoAfrica13.462.375.7
44🇺🇦 UkraineEurope13.361.674.9
45🇹🇳 TunisiaAfrica13.363.676.9
46🇦🇱 AlbaniaEurope13.366.780.0
47🇵🇷 Puerto RicoAmericas13.368.882.1
48🇵🇦 PanamaAmericas13.366.780.0
49🇷🇸 SerbiaEurope13.263.977.1
50🇵🇾 ParaguaySouthern America13.260.974.1
51🇧🇦 Bosnia and HerzegovinaEurope13.265.078.2
52🇵🇹 PortugalEurope13.269.582.7
53🇭🇳 HondurasAmericas13.260.073.2
54🇰🇿 KazakhstanAsia13.161.674.7
55🇾🇪 YemenAsia13.156.569.6
56🇻🇺 VanuatuOceania13.158.771.8
57🇨🇦 CanadaNorthern America13.169.882.9
58🇨🇴 ColombiaSouthern America13.165.078.1
59🇲🇾 MalaysiaAsia13.163.977.0
60🇨🇭 SwitzerlandEurope13.171.184.2
61🇰🇮 KiribatiOceania13.153.666.7
62🇯🇴 JordanAsia13.065.178.1
63🇲🇼 MalawiAfrica13.054.767.7
64🇰🇼 KuwaitAsia13.067.880.8
65🇬🇧 UKEurope13.068.681.6

Their rise reflects both an aging population and expanding preventative treatment for stroke and atrial fibrillation.

With almost four million beneficiaries, Eliquis is prescribed to roughly one in 10 Part D enrollees.

ℹ️ Related: See the 25 countries that are projected have the most seniors in 2050.

Diabetes and Weight-Loss Therapies Surge in America

Four GLP-1 and SGLT2 diabetes drugs—Ozempic, Jardiance, Trulicity, and Farxiga—collectively totaled $29.7 billion.

Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro also double as weight-loss aids, driving demand beyond traditional type-2 diabetes patients.

This table lists cost per dose for the 10 most expensive drugs.

Their high list prices—Ozempic averages $356 per dose—illustrate how novel biologics multiply spending even with smaller patient counts.

ℹ️ Related: See where Americans skipped going to the doctor (even when they had to) in 2023.

Cancer and Autoimmune Biologics are Expensive Drugs

Revlimid, Humira, and Stelara each exceed $3 billion despite treating fewer than 100,000 beneficiaries each.

Revlimid’s $878 per dose and Stelara’s staggering $26,818 underscore why biologics dominate specialty-drug budgets.

Want more health-related data storytelling? Check out Ranked: Countries That Spend the Most Years in Poor Health on Voronoi, the new app from Visual Capitalist.

Loading recommendations...